Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes

Expert Opinion on Drug Metabolism and Toxicology

Volumn 13, Issue 2, 2017, Pages 211-223

  Tomlinson, Brian ^a,b   Hu, Miao ^b   Zhang, Yuzhen ^a   Chan, Paul ^c   Liu, Zhong Min ^d  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TONGJI UNIVERSITY   (China)

Author keywords

Empagliflozin; SGLT2; sodium glucose co transporter 2 inhibitors; type 2 diabetes mellitus; urinary glucose excretion

Indexed keywords

EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL OUTCOME; DEVELOPING COUNTRY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEART FAILURE; HOSPITALIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PATHOLOGY; STATISTICS AND NUMERICAL DATA;

BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GLUCOSE; GLUCOSIDES; HOSPITALIZATION; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84996551945     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2017.1258401     Document Type: Article

References (94)

1. Nathan DM., Diabetes:advances in diagnosis and treatment. JAMA. 2015;314:1052–1062.
2. Nanditha A, Ma RCW, Ramachandran A, et al. Diabetes in Asia and the Pacific:implications for the global epidemic. Diabetes Care. 2016;39:472–485.
3. NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980:a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–1530.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach:update to a position statement of the American diabetes association and the european association for the study of diabetes. Diabetes Care. 2015;38:140–149.
5. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008–2017.
6. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–2298.
7. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD, ADVANCE, and VA diabetes trials:a position statement of the American diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association. Diabetes Care. 2009;32:187–192.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–2471.
9. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events):a randomised controlled trial. Lancet. 2005;366:1279–1289.
10. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus:a meta-analysis of randomized trials. JAMA. 2007;298:1180–1188.
11. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331.
12. U.S. Food and Drug Administration. Guidance for Industry. diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat Type 2 diabetes, December 2008. [cited 2016 June20]. Available from www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
13. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015;14:505–524.
14. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.• The cardiovascular outcome study with saxagliptin.
15. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.• The cardiovascular outcome study with alogliptin.
16. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2015;373:232–242.• The cardiovascular outcome study with sitagliptin.
17. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–1588.
18. Tomlinson B, Hu M, Zhang Y, et al. An overview of new GLP-1 receptor agonists for type 2 diabetes. Expert Opin Investig Drugs. 2016;25:145–158.
19. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373:11–22.
20. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257.• The cardiovascular outcome study with lixisenatide.
21. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2016;375:311–322.• The cardiovascular outcome study with liraglutide.
22. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733–794.• Detailed review of sodium glucose transporters.
23. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs. 2007;8:285–292.
24. Washburn WN, Poucher SM. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2013;22:463–486.
25. Turk E, Zabel B, Mundlos S, et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354–356.
26. Santer R, Calado J. Familial renal glucosuria and SGLT2:from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5:133–141.
27. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012;92:158–169.
28. Hedrington MS, Davis SN. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11:613–623.
29. Seino Y. Luseogliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15:2741–2749.
30. Mikhail N. Remogliflozin etabonate:a novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opin Investig Drugs. 2015;24:1381–1387.
31. Cariou B, Charbonnel B. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2015;24:1647–1656.
32. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
33. American Diabetes Association. 7. Approaches to Glycemic treatment. Diabetes Care. 2016;39(Suppl 1):S52–59.
34. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive Type 2 diabetes management algorithm–2016 executive summary. Endocr Pract. 2016;22:84–113.
35. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor:characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14:83–90.
36. Jahagirdar V, Barnett AH. Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014;15:2429–2441.
37. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152–161.
38. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet. 2013;28:213–219.
39. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613–621.
40. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4:331–345.
41. Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215–222.
42. Sarashina A, Ueki K, Sasaki T, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2014;36:1606–1615.
43. Taub ME, Ludwig-Schwellinger E, Ishiguro N, et al. Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite (M466/2) that degrades to 4-hydroxycrotonaldehyde, a reactive and cytotoxic species. Chem Res Toxicol. 2015;28:103–115.
44. Prescribing information (07/2016):JARDIANCE® (empagliflozin) tablets, for oral use. [cited 2016 Oct18]. Available from:http://docs.boehringer-ingelheim.com/Prescribing%20Inforsmation/PIs/Jardiance/jardiance.pdf
45. European Medicines Agency. Assessment report. Jardiance. International non-proprietary name:empagliflozin. 2014. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf
46. Macha S, Brand T, Meinicke T, et al. Pharmacokinetics and pharmacodynamics of twice daily and once daily regimens of empagliflozin in healthy subjects. Clin Ther. 2015;37:1789–1796.
47. Macha S, Jungnik A, Hohl K, et al. Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:873–879.
48. Macha S, Rose P, Mattheus M, et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. 2014;16:118–123.
49. Riggs MM, Staab A, Seman L, et al. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. J Clin Pharmacol. 2013;53:1028–1038.
50. Tonjes A, Kovacs P. SGLT2:a potential target for the pharmacogenetics of Type 2 diabetes? Pharmacogenomics. 2013;14:825–833.
51. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721–728.
52. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154–1160.
53. Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin:an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–4021.
54. Kadowaki T, Haneda M, Inagaki N, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus:a randomized, 12-week, double-blind, placebo-controlled, phase II trial. Adv Ther. 2014;31:621–638.
55. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes:a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1:208–219.
56. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes:a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014;37:1650–1659.
57. Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes:a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396–3404.
58. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes:a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147–158.
59. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815–1823.
60. Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes:a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700.
61. Kadowaki T, Haneda M, Inagaki N, et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes:a randomized, double-blind, parallel-group study. Adv Ther. 2015;32:306–318.
62. Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with Type 2 diabetes mellitus. Clin Ther. 2015;37:1773–1788, e1771.
63. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease:a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–384.
64. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes:a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
65. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117–2128.•• The first cardiovascular outcome study with a sodium–glucose co-transporter 2 inhibitor.
66. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk:results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37:1526–1534.• Important description of heart failure outcomes with empagliflozin.
67. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in Type 2 diabetes. N Engl J Med. 2016;375:323–334.•• Important study of renal outcomes with empagliflozin.
68. Abdul-Ghani M, del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk:lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39:717–725.
69. Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial:comparison with classic diuretics. Diabetes Metab. 2016;42:224–233.
70. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial:a “thrifty substrate” hypothesis. Diabetes Care. 2016;39:1108–1114.
71. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115–1122.
72. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk:proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90–100.
73. Filippatos TD, Tsimihodimos V, Elisaf MS. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Expert Opin Pharmacother. 2016;17:1581–1583.
74. Perkins BA, Cherney DZI, Soleymanlou N,. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of Empagliflozin in Type 1 diabetes. PLoS One. 2015;10:e0141085.
75. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014;23:875–882.
76. Carlson CJ, Santamarina ML. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with Type 2 diabetes mellitus. Expert Opin Drug Saf. 2016;15:1401–1412.
77. Kohler S, Salsali A, Hantel S, et al. Safety and tolerability of empagliflozin in patients with Type 2 diabetes. Clin Ther. 2016;38:1299–1313.
78. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis:a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38:1638–1642.
79. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis:a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–1693.
80. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors:possible mechanism and contributing factors. J Diabetes Investig. 2016;7:135–138.
81. Drug Safety Communication. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015 Dec 4.[cited 2016 Aug1]. Available from:http://www.fda.gov/downloads/Drugs/DrugSafety/UCM475487.pdf
82. Briand F, Mayoux E, Brousseau E, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032–2038.
83. Drug Safety Communication. FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. 2015 Sep 9. [cited 2016 Aug1]. Available from:http://www.fda.gov/downloads/Drugs/DrugSafety/UCM461790.pdf
84. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
85. Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther. 2012;29:889–899.
86. Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35:A33–A342.
87. Macha S, Dieterich S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:132–140.
88. Macha S, Mattheus M, Pinnetti S, et al. Pharmacokinetics of empagliflozin and pioglitazone after coadministration in healthy volunteers. Clin Ther. 2015;37:1503–1516.
89. Macha S, Koenen R, Sennewald R, et al. Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Clin Ther. 2014;36:280–290, e281.
90. Macha S, Sennewald R, Rose P, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013;35:226–235.
91. Macha S, Lang B, Pinnetti S, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers. Int J Clin Pharmacol Ther. 2014;52:973–980.
92. Macha S, Rose P, Mattheus M, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013;15:316–323.
93. Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction:a randomized clinical trial. JAMA. 2016;316:500–508.• Important study showing lack of benefit of liraglutide in advanced heart failure.
94. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment:what we should know about newer therapies. Clin Pharmacol. 2016;8:61–81.